All In Biotech

Drug Trial Radar · NCT04545866

The Budesonide in Babies (BiB) Trial

Randomized Controlled Trial of Budesonide + Surfactant Versus Surfactant Alone in Extremely Preterm Infants ("The Budesonide in Babies (BiB) Trial")

Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 642 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

642

Actual

Start

Apr 1, 2021

Primary completion

Sep 5, 2024

Study completion Dec 17, 2026

Sponsor

Lead sponsor
NICHD Neonatal Research NetworkResearch network
Sponsor type
Research network
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
Sep 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, up to 48 hours
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 3, randomized, masked, active-controlled, multicenter trial designed to determine whether early intratracheal administration of a combination of budesonide with surfactant, as compared to surfactant alone, will reduce the incidence of physiologic bronchopulmonary dysplasia (BPD) or death by 36 weeks' post-menstrual age in extremely preterm infants.

Conditions

  • Bronchopulmonary Dysplasia (BPD)
  • Respiratory Distress Syndrome
  • Prematurity; Extreme
  • Neonatal

Interventions

  • budesonide (Pulmicort nebulizing suspension).Drug

    The first dose of budesonide is 0.25 mg/kg in a volume of 1 ml/kg, for a total volume of 2.5 ml/kg of Curosurf + 1 ml/kg of budesonide. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose and 1 ml/kg of budesonide.

  • surfactant (poractant alfa;Curosurf)Drug

    The first dose of surfactant (poractant alfa; Curosurf) is 2.5 ml/kg. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Physiologic BPD or Death by 36 Weeks PMATime frame: Randomization to 36 weeks PMA

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama

    Birmingham, Alabama

  • Stanford University

    Palo Alto, California

  • Sharp Mary Birch Hospital for Women & Newborns

    San Diego, California

  • Emory University

    Atlanta, Georgia

  • Northwestern Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Iowa

    Iowa City, Iowa

  • University of Mississippi Medical Center - Children's of Mississippi

    Jackson, Mississippi

  • University of New Mexico

    Albuquerque, New Mexico

  • University of Rochester

    Rochester, New York

  • RTI International

    Durham, North Carolina

  • Duke University

    Durham, North Carolina

  • Cincinnati Children's Medical Center

    Cincinnati, Ohio

  • Case Western Reserve University, Rainbow Babies and Children's Hospital

    Cleveland, Ohio

  • Research Institute at Nationwide Children's Hospital

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Brown University - Women and Infants Hospital of Rhode Island

    Providence, Rhode Island

  • University of Texas Southwestern Medical Center at Dallas

    Dallas, Texas

  • University of Texas Health Science Center at Houston

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.